Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730067 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Comparison of the effectiveness of aliskiren and ramipril for the management of hypertension: A systematic review and meta-analysis.
Hipertens Riesgo Vasc
December 2024
Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia, Hamdard, New Delhi 110062, India.
Objective: Ramipril is an important option in the management of hypertension, while the role of aliskiren is still up for debate. We aim to meta-analyse and compare the effect of aliskiren with ramipril by measuring mean difference in systolic blood pressure (mdSBP) and mean difference in diastolic blood pressure (mdDBP).
Methods: The search was conducted using the PubMed and Cochrane databases for eligible randomized clinical trials (RCTs) to perform a meta-analysis from January 2000 to May 2024.
Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
Circulation
December 2024
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (L.S., P.D., P.S.J., J.J.V.M.).
Background: Cognitive impairment is common in patients with heart failure and preserved ejection fraction but its clinical correlates and prognostic associations are poorly understood.
Methods: We analyzed cognitive function, using the Mini-Mental State Examination (MMSE), in patients with heart failure and preserved ejection fraction enrolled in a prespecified substudy of the PARAGON-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in Heart Failure With Preserved Ejection Fraction). Logistic regression analyses were performed to determine the variables associated with lower MMSE scores at baseline and postbaseline decline in MMSE scores at 48 weeks.
Successful treatment of severe renal failure caused by malignant hypertension using a combination of renin-angiotensin-aldosterone system inhibitors: a case report.
CEN Case Rep
September 2024
Department of Nephrology, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan.
Marked activation of the renin-angiotensin-aldosterone system (RAAS) plays an important role in malignant hypertension (MHT) by worsening hypertension and renal function. The rates of readmission for severe hypertension and cardiovascular disease in such emergencies are high, suggesting that suppression of the RAAS may be inadequate during the acute phase in some cases. This report presents a case of MHT complicated with renal insufficiency (creatinine 3.
View Article and Find Full Text PDFEffects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical Trials.
JAMA Cardiol
November 2024
Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Article Synopsis
- Sacubitril/valsartan is a medication that helps reduce the risk of cardiovascular death and hospital stays due to heart failure in people with chronic heart failure (HF), especially among older patients with other health issues.* -
- The study analyzed data from two major trials (PARADIGM-HF and PARAGON-HF) to determine the impact of sacubitril/valsartan on all-cause hospitalizations in patients with different levels of heart function (measured as left ventricular ejection fraction - LVEF).* -
- Results showed that sacubitril/valsartan lowered the risk of all-cause hospitalization compared to standard heart medications, with a median follow-up of about 2.5
Spontaneous and evoked angiotensin II sniffer cell activity in the lamina terminalis in vitro.
Am J Physiol Regul Integr Comp Physiol
November 2024
Department of Physiology and Anatomy, University of North Texas Health Science Center at Fort Worth, Fort Worth, Texas, United States.
Article Synopsis
- Angiotensin II (ANG II) affects the central nervous system, but the presence of a brain-specific renin-angiotensin system (RAS) is still debated.
- Researchers used modified Chinese hamster ovary cells to measure ANG II release from brain slices of rats, finding that its release is mostly dependent on renin and ACE-1 but might have alternative pathways, particularly in renin knockout rats.
- Findings show that ANG II release increases after chronic intermittent hypoxia, indicating that a unique tissue-specific RAS in the brain could be affected in models of conditions like sleep apnea.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!